Related Experiment Video
Updated: Mar 17, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.5K
The Portuguese Experience with Ocriplasmin in Clinical Practice
João Figueira1, David Martins, Bernardete Pessoa
1Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Ophthalmic Research
|July 21, 2016
Summary
Intravitreal ocriplasmin achieved vitreomacular traction (VMT) release in over half of patients and closed full-thickness macular holes (FTMH) in 50%, improving visual acuity. Careful patient selection optimizes outcomes for VMT resolution.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Vitreomacular traction (VMT) and full-thickness macular holes (FTMH) are significant causes of vision impairment.
- Ocriplasmin is an enzymatic agent investigated for VMT and FTMH treatment.
- Real-world data on ocriplasmin effectiveness in Portugal was previously limited.
Purpose of the Study:
- To evaluate the real-world effectiveness of ocriplasmin in treating VMT and FTMH in Portugal.
- To assess VMT release, FTMH closure, and visual acuity changes post-ocriplasmin treatment.
- To identify factors influencing treatment outcomes.
Main Methods:
- A multicentric, retrospective study involving 83 eyes from 78 patients treated with intravitreal ocriplasmin.
- Primary endpoints included VMT release and FTMH closure rates.
- Secondary endpoints comprised changes in best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) findings.
Main Results:
- VMT resolved in 56.6% of eyes, and FTMH closed in 50.0% of treated cases.
- Mean BCVA significantly improved from baseline (p < 0.0001) over a mean follow-up of 138.8 days.
- Favorable structural outcomes included preserved ellipsoid zone integrity (73%) and reduced intra/subretinal fluid (40%).
Conclusions:
- Ocriplasmin demonstrated efficacy in achieving VMT release and FTMH closure in a real-world setting.
- Treatment success correlated with significant BCVA improvements and favorable baseline patient characteristics.
- Optimized patient selection is crucial for maximizing the benefits of ocriplasmin therapy for VMT and FTMH.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
454
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
454
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
624
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
624
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Venous Thrombosis IV: Nursing Management
360
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
360